AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01648322
Drug: Neulasta® (pegfilgrastim)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose injection given once per chemotherapy cycle.
Trial: NCT01879241
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a sugar pill manufactured to mimic Rasagiline 1 mg tablet
Trial: NCT05781685
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.
Trial: NCT04652297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Placebo
Trial: NCT01369576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75-7.5mg 14 doses 4 weeks
Trial: NCT04652297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of Placebo
Trial: NCT04248153
Drug: BR55
RxNorm normalized name: Band-Aid Ourtone BR55 Bandages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg
Trial: NCT02251041
Drug: Apotransferrin
RxNorm normalized name: melanotransferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02251041
Drug: Glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02251041
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01013259
Drug: Mutaflor
RxNorm normalized name: Duraflor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
Trial: NCT00456521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00009854
Drug: carmustine in ethanol
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00992082
Drug: ropivacaine, ketorolac and epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
Trial: NCT01013259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo capsule matching the experimental treatment, according to the experimental arm
Trial: NCT02074631
Drug: Calcium and vitamin D
RxNorm normalized name: Wellesse Calcium and Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
Trial: NCT01116895
Drug: LEO 22811
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT01116895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04024254
Drug: Folic Acid Tablet
RxNorm normalized name: Folic Acid Tablets
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid 1 mg by mouth daily
Trial: NCT02542280
Drug: ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
Trial: NCT01426880
Drug: background treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients).
Trial: NCT02214628
Drug: Fovista® (anti-PDGF BB) plus anti-VEGF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01566565
Drug: Theophylline and Bambuterol
RxNorm normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
Trial: NCT01460615
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02011542
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a probiotic mixture
Trial: NCT02011542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a pill with inactive ingredients.
Trial: NCT00191698
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01421459
Drug: LY2963016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT01421459
Drug: OAMs
RxNorm normalized name: ALCOHOL 0.7 L in 1 L TOPICAL LIQUID [MG FoamSan 70]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00002985
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006377
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03635879
Drug: AC-1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
Trial: NCT04414930
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects complete 30 sessions of Targeted Cognitive Training (2-3 times per week), and receive placebo po 1 hour prior to each training.
Trial: NCT03377322
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - one capsule a day for four weeks
Trial: NCT04991155
Drug: BIA 5-1058
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
Trial: NCT00740142
Drug: L-ornithine-L-aspartate and lactulose
RxNorm normalized name: ornithine, (L)-isomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
Trial: NCT04056442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive Oil Solution, 5%
Trial: NCT02607891
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Trial: NCT02607891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Trial: NCT01165255
Drug: 3. Exposure to other antidepressants during the first trimester comparison cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy.
Trial: NCT00333866
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03762109
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inactive pill
Trial: NCT02510274
Drug: ASP3325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00050011
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
Trial: NCT04507269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline given by subcutaneous injection
Trial: NCT00323518
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously as 100mL single dose over 15 minutes on day 1
Trial: NCT03615768
Drug: Clindamycin Gel
RxNorm normalized name: clindamycin Topical Gel
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
Trial: NCT03378635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for dasiglucagon
Trial: NCT00648713
Drug: Lamisil® Tablets 250 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg, single dose fed
Trial: NCT00027300
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
Trial: NCT03726879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
Trial: NCT03726879
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.
Trial: NCT03726879
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Trial: NCT02766478
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo pill will be taken orally for 12 weeks.
Trial: NCT04451330
Drug: Doxycycline Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline hyclate delayed release 120 mg placebo tablets was administered orally for 12 weeks.
Trial: NCT02173912
Drug: CJ-30059 (Test)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between.
Trial: NCT03832582
Drug: Annexin
RxNorm normalized name: Annexin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
Trial: NCT01341262
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * INDUCTION THERAPY: 4 mg i.v. once a cycle for 4 cycles (30 days each)~* AFTER PBSC COLLECTION: 4 mg i.v. once (the same day of resumption of Thalidomide)~* AFTER FIRST TRANSPLANTATION: 4 mg i.v. once a cycle (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)
Trial: NCT01341262
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 7 g/sqm + G-CSF 5 mcg/Kg from the day +6 for stem cell mobilisation
Trial: NCT03342950
Drug: Topical Solution
RxNorm normalized name: Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Solution of Clonidine (0.01%) + Pentoxifylline (5%) in anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
Trial: NCT03342950
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Solution of anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
Trial: NCT03129074
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: from Day 1 to Day 14 followed by 7-day of rest period, every 21 days.
Trial: NCT02410980
Drug: Tretinoin cream 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of the skin change
Trial: NCT04075331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution for subcutaneous injection
Trial: NCT03208179
Drug: dihydroartemisinin-piperaquine plus azithromycin
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
Trial: NCT00530257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sugar pill)
Trial: NCT00212030
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT01733407
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/kg/d divided TID for year 1 only.
Trial: NCT03629717
Drug: Calcium
RxNorm normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg daily
Trial: NCT02198248
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.~High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule.
Trial: NCT04482803
Drug: Carbon nanoparticles suspension injection will be injected into or around the cortex of the clinically assessed positive lymph nodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before NST, one of the clinically assesed positive lymph nodes will be subjected to ultrasound-guided CNB or FNA, and a locating clip (Ultraclip, BARD) will be placed. Meanwhile, a small amount of Kanarine (carbon nanoparticles suspension injection, 0.5ml:25mg, H20073246) will be injected into or around the cortex of the locating lymph node and other clinically assessed positive lymph nodes. Preoperative FNA will be performed again for locating clip labelled node.
Trial: NCT01881958
Drug: DiaPep277®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03083080
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
Trial: NCT02667561
Drug: Testosterone gel 1% 2.2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Trial: NCT02667561
Drug: Testosterone gel 1% 4.4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Trial: NCT02667561
Drug: Testosterone gel 1% 8.8 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Trial: NCT02667561
Drug: Placebo of Testosterone Gel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
Trial: NCT05008250
Drug: Tongmai Yangxin Pill (TMYXP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMYXP is a Chinese patent medicine developed by many years of clinical practice experience. The ingredients of TMYXP are Radix Rehmanniae, Caulis Spatholobi, Polygonum Multiflorum, Colla Corii Asini, Ophiopogonis, Tortoise Shell (vinegar), Radix Codonopsis, Cassia Twig, Jujube, Schisandra Fruit, and Licorice Root. It has the effect of invigorating Qi, nourishing Yin, dredging the pulse, and relieving pain. It is used in treatment of Qi and Yin deficiency syndromes caused by coronary heart disease, angina pectoris, and arrhythmia.~Metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
Trial: NCT05008250
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simulated pills
Trial: NCT01526616
Drug: Metformin plus Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
Trial: NCT04347239
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos
Trial: NCT03945396
Drug: Homeopathic Medication
RxNorm normalized name: homeopathic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.
Trial: NCT04359329
Drug: Estradiol patch
RxNorm normalized name: Estradiol Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant receives estradiol 100 micrograms/day for 7 days through a patch applied on the skin
Trial: NCT03945396
Drug: Homeopathic placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 30 ml bottle of 30% alcohol-distilled water.
Trial: NCT00412763
Drug: Silymarin (Silybum marianum)
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00616681
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00403793
Drug: etonogestrel with testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
Trial: NCT00403793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42 or 44 weeks with placebo implant and placebo injections
Trial: NCT01119885
Drug: fentanyl matrix
RxNorm normalized name: FentaNYL Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knee osteoarthritis, starting with 12mcg/h (flexible dose)
Trial: NCT01119885
Drug: fentanyl matrix
RxNorm normalized name: FentaNYL Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hip osteoarthritis, starting with 12mcg/h (flexible dose)
Trial: NCT03330769
Drug: New course of treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of new course of NSAIDs (monotherapy), steroid intra-articular injections (monotherapy), conventional DMARDs, biologic DMARDs, including switches or dose augmentations, indicated by the treating rheumatologist according to usual clinical practice.
Trial: NCT00388271
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment
Trial: NCT04265781
Drug: BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three different doses over the course of study
Trial: NCT04265781
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo to BAY1817080
Trial: NCT02060604
Drug: Ketorolac + Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 monthly ranibizumab, then as needed Ketorolac TID
Trial: NCT00128778
Drug: Pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01326689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03220633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01110512
Drug: Flavonid
RxNorm normalized name: flavodic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day.
Trial: NCT01110512
Drug: Daflon
RxNorm normalized name: Daflonex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day
Trial: NCT01601561
Drug: Regular human insulin injection
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose.
Trial: NCT03574363
Drug: KBP-5074 0.25 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, QD, 84 days
Trial: NCT03574363
Drug: KBP-5074 0.5 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration, QD, 84 days